Mobile

A Study to Assess the Safety and Pharmacokinetics (Serum Levels) of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-004366-18

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the PK of golimumab in pediatric subjects aged 2 through 17 years with moderately to severely active UC. To evaluate the safety of golimumab in pediatric subjects aged 2 through 17 years with moderately to severely active UC.

Critère d'inclusion

  • Ulcerative Colitis in pediatric subjects

Liens